High-Grade Osteosarcoma of the Foot: Presentation, Treatment, Prognostic Factors, and Outcome of 23 Cooperative Osteosarcoma Study Group COSS Patients
Anne J. Schuster,
Leo Kager,
Peter Reichardt,
Daniel Baumhoer,
Monika Csóka,
Stefanie Hecker-Nolting,
Susanna Lang,
Sylvie Lorenzen,
Regine Mayer-Steinacker,
Thekla von Kalle,
Matthias Kevric,
Mathias Werner,
Reinhard Windhager,
Thomas Wirth,
Stefan S. Bielack
Affiliations
Anne J. Schuster
Center for Pediatric, Adolescent and Women's Medicine, Olgahospital, Department of Pediatrics 5 (Oncology, Hematology, Immunology), Klinikum Stuttgart, Stuttgart, Germany
Leo Kager
St. Anna Children’s Hospital, Department of Paediatrics, Medical University of Vienna and Children’s Cancer Research Institute (CCRI), Vienna, Austria
Peter Reichardt
Department of Interdisciplinary Oncology, HELIOS Klinikum Berlin-Buch, Berlin, Germany
Daniel Baumhoer
Bone Tumour Reference Centre (BTRC), Institute of Pathology, University Hospital of Basel and University of Basel, Basel, Switzerland
Monika Csóka
2nd Department of Pediatrics, Semmelweis University, Budapest, Hungary
Stefanie Hecker-Nolting
Center for Pediatric, Adolescent and Women's Medicine, Olgahospital, Department of Pediatrics 5 (Oncology, Hematology, Immunology), Klinikum Stuttgart, Stuttgart, Germany
Susanna Lang
Department of Pathology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria
Sylvie Lorenzen
Department of Hematology and Oncology, Klinikum rechts der Isar Technische Universität München, Munich, Germany
Regine Mayer-Steinacker
Department of Internal Medicine III, University of Ulm, Ulm, Germany
Thekla von Kalle
Center for Pediatric, Adolescent and Women’s Medicine, Olgahospital, Department of Pediatric Radiology, Klinikum Stuttgart, Stuttgart, Germany
Matthias Kevric
Center for Pediatric, Adolescent and Women's Medicine, Olgahospital, Department of Pediatrics 5 (Oncology, Hematology, Immunology), Klinikum Stuttgart, Stuttgart, Germany
Mathias Werner
Department of Interdisciplinary Oncology, HELIOS Klinikum Berlin-Buch, Berlin, Germany
Reinhard Windhager
Department of Orthopaedics, Medical University of Vienna, Vienna, Austria
Thomas Wirth
Center for Pediatric, Adolescent and Women’s Medicine, Olgahospital, Department of Pediatrics, Division of Pediatric Orthopedics, Klinikum Stuttgart, Stuttgart, Germany
Stefan S. Bielack
Center for Pediatric, Adolescent and Women's Medicine, Olgahospital, Department of Pediatrics 5 (Oncology, Hematology, Immunology), Klinikum Stuttgart, Stuttgart, Germany
Osteosarcoma of the foot is a very rare presentation of a rare tumor entity. In a retrospective analysis, we investigated tumor- and treatment-related variables and outcome of patients registered in the Cooperative Osteosarcoma Study Group (COSS) database between January 1980 and April 2016 who suffered from primary high-grade osteosarcoma of the foot. Among the 23 eligible patients, median age was 32 years (range: 6–58 years), 10 were female, and 13 were male. The tarsus was the most commonly affected site (n=16). Three patients had primary metastases. All patients were operated: 5 underwent primary surgery and 18 received surgery following preoperative chemotherapy. In 21 of the 23 patients, complete surgical remission was achieved. In 4 of 17 patients, a poor response to neoadjuvant chemotherapy was observed in the resected primary tumors. Median follow-up was 4.2 years (range: 0.4–18.5). At the last follow-up, 15 of the 23 patients were alive and 8 had died. Five-year overall and event-free survival estimates were 64% (standard error (SE) 12%) and 54% (SE 13%), which is similar to that observed for osteosarcoma in general. Event-free and overall survival correlated with primary metastatic status and completeness of surgery. Our findings show that high-grade osteosarcoma in the foot has a similar outcome as osteosarcoma of other sites.